Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Issued (2016 - 2025)

Historic Shares Issued for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $46.8 million.

  • Arrowhead Pharmaceuticals' Shares Issued rose 8732.8% to $46.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $263.2 million, marking a year-over-year decrease of 4202.18%. This contributed to the annual value of $241.4 million for FY2025, which is 4376.71% down from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Shares Issued is $46.8 million, which was up 8732.8% from $216.4 million recorded in Q1 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Shares Issued registered a high of $429.0 million during Q1 2024, and its lowest value of $267000.0 during Q4 2023.
  • For the 5-year period, Arrowhead Pharmaceuticals' Shares Issued averaged around $52.4 million, with its median value being $1.9 million (2021).
  • Its Shares Issued has fluctuated over the past 5 years, first plummeted by 9798.11% in 2023, then surged by 8239961.54% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Shares Issued (Quarter) stood at $1.9 million in 2021, then plummeted by 69.44% to $576000.0 in 2022, then plummeted by 53.65% to $267000.0 in 2023, then surged by 9263.3% to $25.0 million in 2024, then skyrocketed by 87.33% to $46.8 million in 2025.
  • Its Shares Issued stands at $46.8 million for Q4 2025, versus $216.4 million for Q1 2025 and $25.0 million for Q4 2024.